← NATIONAL HEALTH INVESTORS INC
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Net Income (Loss) Attributable to Parent | $151.5m |
$159.4m
+5.16%
|
$154.3m
-3.16%
|
$160.5m
+3.97%
|
$185.1m
+15.37%
|
$111.8m
-39.61%
|
$66.4m
-40.61%
|
$135.7m
+104.29%
|
$138.0m
+1.72%
|
$142.2m
+3.04%
|
— | |
| Net Income (Loss) Available to Common Stockholders, Basic | $152.7m |
$159.4m
+4.35%
|
$154.3m
-3.16%
|
$160.4m
+3.96%
|
$185.3m
+15.50%
|
$112.0m
-39.58%
|
$65.5m
-41.50%
|
$135.6m
+107.02%
|
$137.9m
+1.67%
|
$142.0m
+2.98%
|
— | |
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | $152.7m | $159.4m | $154.3m | $160.4m | $185.3m | $112.0m | $65.5m | $134.4m | $136.6m | $140.8m | — | |
| Net Income (Loss) Attributable to Noncontrolling Interest | $1.2m | $0 | $0 | ($7k) | $185k | $163k | ($902k) | ($1.3m) | ($1.3m) | ($1.4m) | — | |
| Depreciation and amortization | $59.6m | $67.2m | $71.3m | $76.8m | $83.2m | $80.8m | $70.9m | $70.0m | $71.4m | $80.9m | $85.5m | |
| Amortization of Debt Issuance Costs | $3.6m | $5.8m | $4.4m | $5.1m | $5.4m | $4.4m | $4.3m | $4.7m | $6.6m | $3.4m | — | |
| Amortization of Deferred Charges | $669k | $1.0m | $608k | $440k | $806k | $741k | — | — | — | — | — | |
| Deferred Income Tax Expense (Benefit) | $707k | — | — | — | — | — | — | — | — | — | — | |
| Payment, Tax Withholding, Share-based Payment Arrangement | $1.1m | $571k | $1.8m | $1.6m | $2.7m | $0 | $288k | $0 | $5.8m | $456k | — | |
| Share-based Payment Arrangement, Expense | $1.7m | $2.6m | $2.5m | $3.6m | $3.1m | $8.4m | $8.6m | $4.6m | $4.2m | $5.6m | $5.3m | |
| Income (Loss) from Equity Method Investments | ($1.2m) | $0 | $0 | — | ($3.1m) | ($1.5m) | $569k | $555k | $402k | $3.7m | — | |
| Financing Receivable Excluding Accrued Interest Credit Loss Expense Reversal | — | — | — | — | — | — | — | $138k | $4.8m | $3.5m | — | |
| Net Cash Provided by (Used in) Operating Activities | $177.2m |
$197.3m
+11.35%
|
$207.9m
+5.34%
|
$241.0m
+15.92%
|
$232.1m
-3.66%
|
$210.9m
-9.17%
|
$185.3m
-12.10%
|
$184.4m
-0.48%
|
$207.8m
+12.64%
|
$236.6m
+13.86%
|
$243.5m
+2.94%
|
|
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Property, Plant, and Equipment | $394.7m | $175.8m | $147.6m | $237.2m | $116.7m | $50.3m | $11.0m | $49.6m | $157.9m | $294.0m | ($4.1m) | |
| Gain (Loss) on Sale of Investments | — | — | — | — | — | — | — | — | ($6.3m) | — | — | |
| Net Cash Provided by (Used in) Investing Activities | ($329.8m) | ($163.8m) | ($250.3m) | ($342.5m) | ($89.7m) | $185.3m | $197.9m | ($11.6m) | ($192.3m) | ($269.1m) | ($297.6m) | |
| Cash flows from financing activities: | ||||||||||||
| Gain (Loss) on Extinguishment of Debt | — | ($2.2m) | ($738k) | ($823k) | ($3.9m) | ($1.9m) | ($151k) | ($73k) | $0 | $0 | — | |
| Repayments of Long-term Debt | $767k | $250.8m | $1.1m | $1.2m | $43.7m | $293.3m | $135.4m | $415.4m | $75.4m | $200.8m | ($911.9m) | |
| Payments for Repurchase of Common Stock | — | — | — | — | — | — | $152.0m | $0 | $0 | — | — | |
| Proceeds from Issuance of Common Stock | $104.2m | $122.2m | $81.8m | $95.8m | $34.6m | $47.9m | $0 | $0 | $142.4m | $181.5m | $116.0m | |
| Dividends paid | $138.3m | $153.0m | $165.4m | $179.7m | $194.6m | $182.9m | $161.8m | $156.2m | $156.5m | $169.7m | ($173.0m) | |
| Dividends Payable | $35.9m | $39.5m | $42.7m | $46.8m | $49.8m | $41.3m | $39.0m | $39.1m | $41.1m | $44.4m | — | |
| Net Cash Provided by (Used in) Financing Activities | $144.2m |
($35.1m)
-124.31%
|
$44.3m
+226.26%
|
$107.3m
+142.49%
|
($111.8m)
-204.14%
|
($403.0m)
-260.58%
|
($401.3m)
+0.43%
|
($169.7m)
+57.70%
|
($13.6m)
+92.01%
|
$25.7m
+289.48%
|
($58.3m)
-326.73%
|
|
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | — | — | — | — | $30.7m | ($6.9m) | ($18.0m) | $3.1m | $1.9m | ($6.9m) | $24.9m | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | — | $9.9m | $15.7m | $46.3m | $39.5m | $21.5m | $24.6m | $26.5m | $19.6m | $24.9m | |
| Additional Supplementary Disclosures | ||||||||||||
| Additional Supplementary Disclosures | ||||||||||||
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating Activities | $39.5m | $43.2m | $45.9m | $54.0m | $43.4m | $43.7m | $42.7m | $51.9m | $55.4m | $51.5m | — | |
| Additional Financial Items | ||||||||||||
| Gain (Loss) on Sale of Derivatives | — | — | — | — | — | — | — | — | $6.3m | $0 | — | |
| Gain (Loss) on Sale of Properties | $4.6m | $50k | $0 | $0 | — | — | — | — | — | — | — | |
| Gain (Loss) on Sales of Loans, Net | $1.7m | — | — | — | — | — | — | — | — | — | — | |
| Gain (Loss) on Termination of Lease | — | — | — | — | — | — | ($710k) | $20k | $0 | $0 | — | |
| Gains (Losses) on Sales of Investment Real Estate | $4.6m | $50k | $0 | $0 | $21.3m | $32.5m | $28.3m | $14.7m | $6.7m | $456k | — | |
| General and Administrative Expense | $9.8m | $12.2m | $12.5m | $13.4m | $13.3m | $18.4m | $22.8m | $19.3m | $20.7m | $26.9m | — | |
| Income Tax Expense (Benefit) | $854k | $124k | $138k | — | — | — | — | — | — | — | — | |
| Operating Expenses | $129.7m | $127.2m | $139.5m | $156.8m | $161.8m | $216.1m | $241.9m | $200.9m | $211.9m | $239.0m | — | |
| Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax | ($3.9m) | ($2.6m) | ($164k) | $791k | ($6.3m) | — | — | — | — | — | — | |
| Proceeds from Noncontrolling Interests | — | — | — | $643k | $13k | $0 | $11.7m | $3.0m | $1.2m | $1.7m | — | |
| Proceeds from Stock Options Exercised | $1k | $0 | $0 | — | — | — | — | — | — | — | — | |
| Financing Receivable, Credit Loss, Expense (Reversal) | — | — | — | — | $593k | $193k | $10.6m | — | — | — | — |